Detection of novel therapies using a multi‐national, multi‐institutional registry of cutaneous immune‐related adverse events and management

Cutaneous immune‐related adverse events (cirAEs) remain a prevalent and common sequelae of immune checkpoint inhibitor (ICI) therapy, often necessitating treatment interruption and prolonged immune suppression. Treatment algorithms are still poorly defined, based on single‐institution case reports without adequate safety assessments, and subject to publication bias.

[1]  E. Nadelmann,et al.  Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review. , 2021, JAMA oncology.

[2]  Matthew J. Frigault,et al.  NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  A. Amini,et al.  Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma , 2020, JAAD case reports.

[4]  J. Pothen,et al.  A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report , 2019, Cureus.

[5]  R. Motzer,et al.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Ko,et al.  Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single‐institution retrospective analysis with stratification of reactions by toxicity and implications for management , 2019, Journal of the American Academy of Dermatology.

[7]  T. Olencki,et al.  Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab‐induced bullous pemphigoid , 2018, International journal of dermatology.

[8]  M. Lacouture,et al.  Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails , 2018, American Journal of Clinical Dermatology.

[9]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[10]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  S. Granter,et al.  Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. , 2017, JAMA dermatology.

[12]  A. Daud,et al.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. , 2015, JAMA dermatology.

[13]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.